SEC Form 4 · accession 0001493152-26-039124
Grace Therapeutics, Inc. · GRCE
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Opaleye Management Inc.
10% Owner
Period of report
Aug 14, 2026
Accepted (ET)
Aug 19, 2026 · 7:44 am EDT
Rule 10b5-1 plan
box not checked
Issuer CIK
0001444192
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock, par value $0.0001 per shareF2,F1,F3 | Aug 14, 2026 | P | 11,608 | $2.0853 | A | 2,760,000 | I | By Opaleye, L.P. |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1Represents securities owned directly by Opaleye, L.P. (the "Fund"). As the investment manager of the Fund, Opaleye Management, Inc. may be deemed to beneficially own the securities owned directly by the Fund.
- F2The price reported is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $2.05 to $2.09. The reporting person undertakes to provide, upon request by the SEC staff, the issuer, or a security holder of the issuer, full information regarding the number of shares purchased at each separate price within the range.
- F3Opaleye Management, Inc. disclaims beneficial ownership of the shares reported herein except to the extent of its pecuniary interest therein, and the filing of this Form 4 shall not be construed as an admission that Opaleye Management, Inc. is the beneficial owner of any such shares for purposes of Section 16(a) of the Securities Exchange Act of 1934, as amended, or for any other purpose.